Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
07:30am, Thursday, 30'th Oct 2025
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Labo
Asset Management One Co. Ltd. Has $5.94 Million Stock Position in Incyte Corporation $INCY
03:38am, Wednesday, 29'th Oct 2025
Asset Management One Co. Ltd. lowered its position in shares of Incyte Corporation (NASDAQ: INCY) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securit
Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio
05:51pm, Tuesday, 28'th Oct 2025
Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS,
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
02:44pm, Tuesday, 28'th Oct 2025
Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
12:11pm, Tuesday, 28'th Oct 2025
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript
11:41am, Tuesday, 28'th Oct 2025
Incyte Corporation (NASDAQ:INCY ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Alexis Smith William Meury - CEO, President & Director Pablo Cagnoni - President and Head of R
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
10:30am, Tuesday, 28'th Oct 2025
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Oct 2025
Incyte (INCY) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.07 per share a year ago.
Incyte boosts annual sales forecast of blood cancer drug after strong quarter
08:02am, Tuesday, 28'th Oct 2025
Drugmaker Incyte Corp on Tuesday raised its annual sales forecast for its blood cancer treatment Jakafi after robust demand for the drug helped the company surpass Wall Street estimates for third-quar
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Tuesday, 28'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates.
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
07:30am, Monday, 27'th Oct 2025
WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)---- $INCY--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System.
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
07:55pm, Saturday, 25'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ISAD2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis.
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
11:02am, Friday, 24'th Oct 2025
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Thursday, 23'rd Oct 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
